- Median duration of response reached approx. 15 months vs. 9.5 months historical benchmark for FDA-approved monotherapy.
- 100% of responding patients survived beyond 12 months in advanced SCAC cohort.
- Company plans advancement leveraging FDA Fast Track designation.
?? Positive AI Sentiment (+4.5 / 10)